Literature DB >> 17982862

[Seroprevalence of toxoplasmosis in pregnant women in Rabat, Morocco].

B El Mansouri1, M Rhajaoui, F Sebti, F Amarir, M Laboudi, R Bchitou, M Hamad, M Lyagoubi.   

Abstract

In Morocco, the seroprevalence of toxoplasmosis in pregnant women living in Rabat, was estimated by analyzing antibodies (IgG, IgM) levels using an ELISA test. The analysis of 2456 serums at the Institut National d'Hygiène showed that the seroprevalence of toxoplasmosis is about 50.6%. According to the questionnaire, the lack of knowledge about this disease and soil contact could be the main causes of toxoplasmosis infection. The use of IgG avidity test has excluded a recent infection in 93.5% of pregnant women with IgM positive sera.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982862

Source DB:  PubMed          Journal:  Bull Soc Pathol Exot        ISSN: 0037-9085


  14 in total

1.  Sero-epidemiology and risk factors for Toxoplasma gondii among pregnant women in Arab and African countries.

Authors:  Mohamed Alkhatim Alsammani
Journal:  J Parasit Dis       Date:  2014-09-20

2.  Seroprevalence of Toxoplasma gondii infection among immigrant and native pregnant women in Eastern Spain.

Authors:  José M Ramos; Afredo Milla; Juan C Rodríguez; Sergio Padilla; Mar Masiá; Félix Gutiérrez
Journal:  Parasitol Res       Date:  2011-05-04       Impact factor: 2.289

3.  Toxoplasmosis among pregnant women: high seroprevalence and risk factors in Kinshasa, Democratic Republic of Congo.

Authors:  Yobi Doudou; Piarroux Renaud; L'Ollivier Coralie; Franck Jacqueline; Situakibanza Hypolite; Muhindo Hypolite; Mitashi Patrick; Inocêncio da Luz Raquel Andreia; Marc Van Sprundel; Boelaert Marleen; Jean-Pierre Van Geertruyden; Lutumba Pascal
Journal:  Asian Pac J Trop Biomed       Date:  2014-01

4.  [Serological analysis of toxoplasmosis during pregnancy: risk assessment and perspectives of prenatal screening at the University Hospital of Bobo Dioulasso in Burkina Faso].

Authors:  Sanata Bamba; Der Adolphe Some; Cathy Chemla; Régine Geers; Tinga Robert Guiguemde; Isabelle Villena
Journal:  Pan Afr Med J       Date:  2012-06-22

5.  Seroprevalence and risk factors of Toxoplasma gondii infection in pregnant women following antenatal care at Mizan Aman General Hospital, Bench Maji Zone (BMZ), Ethiopia.

Authors:  Fira Abamecha; Hasen Awel
Journal:  BMC Infect Dis       Date:  2016-09-01       Impact factor: 3.090

6.  Immunity Status of Blood Donors Regarding Toxoplasma gondii Infection in a Low-Income District of Abidjan, Côte d'Ivoire, West Africa.

Authors:  Liliane Siransy; Sery Romuald Dasse; Serge Pacôme Dou Gonat; Antoinette Legbedji; Koffi N'guessan; Patricia Ama Kouacou; Richard Yeboah; Hervé Menan
Journal:  J Immunol Res       Date:  2016-10-03       Impact factor: 4.818

7.  Epidemiology and aetiology of maternal parasitic infections in low- and middle-income countries.

Authors:  Tom Roberts; Courtney A Gravett; Prasad Palani Velu; Evropi Theodoratou; Thor A Wagner; Jian Shayne F Zhang; Harry Campbell; Craig E Rubens; Michael G Gravett; Igor Rudan
Journal:  J Glob Health       Date:  2011-12       Impact factor: 4.413

8.  Seroprevalence of Toxoplasma gondii and associated risk factors among pregnant women in Jimma town, Southwestern Ethiopia.

Authors:  Endalew Zemene; Delenasaw Yewhalaw; Solomon Abera; Tariku Belay; Abdi Samuel; Ahmed Zeynudin
Journal:  BMC Infect Dis       Date:  2012-12-05       Impact factor: 3.090

9.  Sero-prevalence and factors associated with Toxoplasma gondii infection among pregnant women attending antenatal care in Mwanza, Tanzania.

Authors:  Berno Mwambe; Stephen E Mshana; Benson R Kidenya; Anthony N Massinde; Humphrey D Mazigo; Denna Michael; Charles Majinge; Uwe Groß
Journal:  Parasit Vectors       Date:  2013-08-06       Impact factor: 3.876

10.  Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries.

Authors:  Jaroslav Flegr; Joseph Prandota; Michaela Sovičková; Zafar H Israili
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.